NCT00005878已完成2 期
Chemoprevention for Barrett's Esophagus Trial (CBET)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 8
研究概览
简要总结
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing cancer in patients with Barrett's esophagus.
PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing cancer in patients who have Barrett's esophagus.
详细描述
OBJECTIVES:
- Determine the safety and efficacy of celecoxib for regression of Barrett's dysplasia in patients with low or high-grade dysplasia of the esophagus.
OUTLINE: This is a randomized, parallel, double-blind, placebo-controlled, multicenter study. Patients are stratified according to center and grade of dysplasia at baseline (low vs high). Patients are randomized to one of two treatment arms.
- Arm I: Patients receive oral celecoxib twice daily for 48-96 weeks.
- Arm II: Patients receive oral placebo as in arm I. Treatment continues in both arms in the absence of unacceptable toxicity or development of adenocarcinoma of the esophagus or cancer at other sites.
Patients are followed at 12 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed Barrett's dysplasia with specific information on the location (level) of the highest grade of dysplasia based on biopsy from baseline endoscopy
- •Short segment Barrett's esophagus must be sufficient area to allow for biopsy without complete resection
- •No presence of reflux esophagitis grades 2-4
- •No history of confirmed invasive carcinoma of the esophagus
- •No diagnosis of esophageal, gastric, pyloric channel, or duodenal ulceration of 1 cm or more in diameter within the past 30 days
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status:
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •Hemoglobin at least 9 g/dL
- •Platelet count greater than 125,000/mm^3
- •WBC greater than 3,000/mm^3
- •No significant bleeding disorder
- •No other abnormal hematopoietic laboratory test result that would preclude study
- •PT/PTT no greater than 1.5 times upper limit of normal (ULN)
- •AST/ALT less than 1.5 times ULN
- •Alkaline phosphatase less than 1.5 times ULN
- •No chronic or acute hepatic disorder
- •No abnormal hepatic laboratory test result that would preclude study
- •Creatinine no greater than 1.5 times ULN
- •No chronic or acute renal disorder
- •No other abnormal renal laboratory test result that would preclude study
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •No prior or concurrent active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)
- •No other prior or concurrent curatively treated malignancy with a survival prognosis of less than 5 years
- •No hypersensitivity or adverse reaction to COX-2 inhibitors (e.g., celecoxib), sulfonamides, salicylates, or NSAIDs
- •No other significant medical, psychological, or psychosocial condition that would preclude study participation
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •Not specified
- •Chemotherapy:
- •Not specified
- •Endocrine therapy:
- •At least 6 months since prior regular (at least 2 weeks duration) oral or intravenous corticosteroids
- •At least 6 months since prior regular (at least 4 weeks duration) inhaled corticosteroids
- •No concurrent regular oral or intravenous corticosteroids
- •No concurrent regular inhaled corticosteroids
- •Concurrent corticosteroid nasal spray allowed
- •Radiotherapy:
- •At least 12 weeks since prior radiotherapy to the chest or upper abdomen
- •At least 3 months since prior surgery to the esophagus or stomach except hiatal hernia repair, fundoplication, vagotomy, or pyloroplasty
- •No prior complete mucosal resection using any technique
- •No concurrent resection of high-grade nodule
- •At least 30 days since prior chronic (at least 3 times a week for greater than 2 weeks) aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs) (i.e., greater than 100 mg/day)
- •No prior complete mucosal ablation using any technique
- 另有 5 项未显示
排除标准
- 未提供
研究者
研究点 (8)
Loading locations...
相似试验
撤回
不适用
Ductal Lavage in Assessing Women With Early Breast Cancer or at High Risk of Developing Breast Cancer and Who Are Eligible For Tamoxifen TherapyBreast CancerNCT00083044Northwestern University
已完成
3 期
Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically RemovedColorectal CancerNCT00002527Alliance for Clinical Trials in Oncology635
终止
2 期
Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast CancerBreast CancerNCT00096369University of Texas Southwestern Medical Center130
Unknown
1 期
Erlotinib in Treating Patients With Barrett EsophagusPrecancerous ConditionEsophageal CancerNCT00566800Kansas City Veteran Affairs Medical Center25
已完成
2 期
Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck CancerHead and Neck CancerNCT00064298Wake Forest University Health Sciences134